A small randomized trial offers evidence that oral micronized progesterone can reduce the combined burden of hot flashes and night sweats in selected, healthy women after menopause. Its central result was an adjusted difference of −4.3 symptom-score units versus placebo over the final four weeks of treatment. That is a meaningful research finding, but it is not a finding of 4.3 fewer hot flashes a day, a percentage reduction, or a guarantee of individual relief.

The capsule questions are unusually important here: Who entered the study? What did their diaries measure? How many randomized women contributed to the analysis? And how should bedtime exposure be understood alongside warnings about drowsiness? This analysis uses the indexed primary report abstract, the available full research article for a separate perimenopause trial, and official US labeling and FDA material. It does not assume access to the postmenopausal trial’s full protocol or supplements.

Postmenopausal progesterone trial: adjusted vasomotor symptom-score difference. Oral progesterone versus placebo: -4.3. Adjusted symptom-score difference versus placebo (95% CI)
A 12-week placebo-controlled trial randomized 133 selected healthy postmenopausal women aged 44–62. The reported analysis included participants with run-in and on-treatment symptom data: 68 progesterone and 46 placebo. The endpoint combined daytime and nighttime symptom frequency multiplied by severity. The estimate is in symptom-score units, not episodes per day or percent improvement. Whiskers show the reported 95% confidence interval. Twelve participants discontinued with adverse events (eight progesterone, four placebo); no serious cases were reported. Historical trial exposure does not establish a US hot-flash indication for progesterone alone, or a dosing instruction.
In this article

Study facts at a glance

Population: 133 healthy volunteers aged 44–62, between 1 and 10 years after their final menstrual period, were randomized. Source 1

Historical study exposure: The active arm received oral micronized progesterone, 300 mg at bedtime, for 12 weeks after a four-week diary run-in. This identifies the research arm, not a dosing recommendation. Source 1

Primary finding: The adjusted between-group VMS-score difference was −4.3 points, with a 95% confidence interval of −6.6 to −1.9. Source 1

Analysis denominator: The reported analysis included 114 women with baseline and on-treatment symptom data: 68 assigned progesterone and 46 assigned placebo. Source 1

Safety and labeling: Adverse-event discontinuations numbered 8 with progesterone and 4 with placebo; no serious cases were reported. The US PROMETRIUM label does not list progesterone-alone hot-flash treatment as an indication. Source 1 Source 2

A deliberately selected postmenopausal population

The study recruited community volunteers between 2003 and 2009. Participants had vasomotor symptoms, or VMS—the research term for hot flashes and night sweats—and were 1–10 years beyond their final menstruation. Their ages ranged from 44 to 62. This was therefore a study of selected women relatively early after menopause, not a broad sample of everyone seeking menopause care.

Eligibility included screening for cardiovascular risk through clinical assessment, physical examination, or laboratory testing. Participants were nonsmokers, had body mass index below 35, normal lipids and electrocardiograms, and no diabetes. Those restrictions help define the population in which benefit was demonstrated. They also leave unanswered how the same exposure would perform in women with different health histories.

At baseline, the average VMS score was 17.0, with a standard deviation of 10.4; average frequency was 6.8 episodes daily, with a standard deviation of 3.2. The substantial variation means that the typical starting burden was not shared by every participant. An average treatment effect likewise cannot describe each woman’s experience.

Source 1

Read the underlying chart data: download CSV or download the source-labeled chart.

What the capsule comparison actually tested

This was a randomized, double-blind, placebo-controlled trial. Random assignment compared oral micronized progesterone with placebo; double blinding meant that treatment assignment was concealed from participants and investigators during the comparison. These design features help distinguish a treatment effect from expectations and from differences that might otherwise influence which women receive treatment.

A four-week run-in preceded 12 weeks of intervention. The active research arm used 300 mg daily at bedtime. That historical exposure describes the experiment; it does not establish a routine regimen or an approved hot-flash dose. The trial also did not compare progesterone with estrogen-based therapy or another active symptom treatment.

The primary endpoint covered the final 28 treatment days, rather than the entire intervention. It therefore estimates symptom burden near the end of three months, not immediate onset of action or durability over years. The guide to what oral progesterone is being prescribed to do helps separate this symptom-treatment question from other reasons a capsule may appear in a hormone plan.

Source 1 Source 2

A diary score combines frequency with severity

Participants recorded daily symptom frequency and severity using the Daily Menopause Diary. Severity ranged from 1 to 4. The daily score added daytime frequency multiplied by daytime severity to nighttime frequency multiplied by nighttime severity. The primary outcome was the average daily score during the final 28 days, analyzed with the run-in score as a covariate—a statistical adjustment for starting symptom burden.

An illustrative calculation shows why score units are not episodes. Three daytime events rated at severity 3 contribute 9 points; two nighttime events rated at severity 2 contribute 4, producing a total of 13. If daytime severity falls to 1 while event counts stay unchanged, the score drops by 6 points without any reduction in the number of episodes.

Conversely, fewer events can lower the score even when severity remains unchanged. Combining both dimensions is useful for measuring overall symptom burden, but it limits interpretation. The reported score difference alone cannot reveal how much benefit came from frequency, severity, daytime symptoms, or night sweats.

Reading the postmenopausal trial’s main numbers

MeasureReported valueWhat it describes
Run-in VMS scoreMean 17.0; SD 10.4Starting frequency-weighted severity, not episodes per day
Run-in VMS frequencyMean 6.8 episodes/day; SD 3.2An event count, distinct from the VMS score
Adjusted treatment difference−4.3; 95% CI −6.6 to −1.9Lower final-period score with progesterone versus placebo
Progesterone-arm change−10.0; 95% CI −12.0 to −8.1Within-arm score reduction, not the placebo-controlled effect
Placebo-arm change−4.4; 95% CI −6.6 to −2.2Improvement also occurred in the comparator arm

Source 1

Why the adjusted difference is not 5.6 points

The progesterone arm’s reported mean score reduction was 10.0 points, while the placebo arm’s reduction was 4.4 points. Simple subtraction gives 5.6 points. However, the primary reported comparison was the baseline-adjusted difference of −4.3. Those are different statistical quantities, and substituting the arithmetic subtraction would misstate the trial’s principal estimate.

The adjusted estimate’s 95% confidence interval ran from −6.6 to −1.9. Because the entire interval is below zero, the result supports a lower average score with progesterone under the analysis used. The interval also shows uncertainty about effect size: the evidence is compatible with a smaller or larger average score advantage within that range.

This is not a confidence interval for an individual woman’s response. Nor does dividing 4.3 by the pooled baseline score produce a reported percentage treatment effect. Without participant-level response categories or a clear episode-count comparison in the abstract, the result cannot establish the probability of complete relief or a number needed to treat.

Source 1

The placebo improvement belongs in the explanation

Both groups improved. The placebo arm’s 4.4-point reduction means that the active arm’s full 10-point decline cannot all be credited to progesterone. A controlled trial asks whether outcomes differ between assigned treatments, not merely whether symptoms decline after a capsule is started.

Several processes could contribute to improvement in both arms: symptoms fluctuate, people may enter research during a particularly troublesome period, and expectations or diary participation may influence reported experience. These are possible interpretations, not mechanisms established by this abstract. The placebo-controlled difference is valuable precisely because the study need not identify every reason symptoms changed in the comparator group.

The four-week run-in supplied a richer baseline than a single recollection at enrollment. Likewise, averaging the last 28 days reduces dependence on one unusually good or bad day. Neither feature eliminates variation, but both make the endpoint more representative of a sustained reporting period than a single end-of-study question.

Source 1

Randomized participants and analyzed participants differ

Of 133 women randomized, 75 were assigned progesterone and 58 placebo. The analysis included women with VMS data at run-in and during therapy: 68 and 46, respectively. Thus, 114 contributed to the reported analysis, 19 fewer than the randomized total. Describing all 133 as complete analyzed participants would be incorrect.

Calculated from these counts, approximately 91% of the progesterone group and 79% of the placebo group contributed qualifying data. These percentages describe analysis inclusion, not necessarily completion of every planned diary day or all 12 treatment weeks. The abstract does not provide enough detail to reconstruct every missing-data pathway.

Randomization protects the initial comparison, but excluding participants without required outcome data can weaken that protection if missingness relates to symptoms or treatment experience. The accessible abstract does not establish the direction or size of any resulting bias. It also does not identify funding, so support disclosed for the separate perimenopause study should not be assigned to this trial.

Source 1

Adverse-event withdrawals require the right denominator

The abstract reports discontinuation with adverse events in 9% overall: eight women in the progesterone arm and four in the placebo arm. Together, those are 12 of 133 randomized participants. The 9% is not an arm-specific rate applying equally to both treatments.

Using randomized denominators, the counts correspond to approximately 10.7% with progesterone and 6.9% with placebo. Those are descriptive calculations, not an adjusted safety comparison. Small counts and the absence of a reported confidence interval make it inappropriate to claim that the trial established a precise excess withdrawal risk.

No serious cases were reported, but the abstract does not list each adverse event responsible for discontinuation. In particular, it does not quantify sedation in this trial. A short study of screened healthy volunteers provides limited evidence about uncommon or delayed harms. The drowsiness and daily-safety guide addresses a distinct issue raised by official capsule labeling, rather than filling in missing trial results.

Source 1 Source 2

Bedtime exposure does not turn sedation into a sleep outcome

The US PROMETRIUM label warns about transient dizziness and drowsiness, including potentially marked symptoms, and cautions about driving or operating machinery. Those warnings matter when interpreting a bedtime capsule study. Feeling sleepy is not equivalent to demonstrating restorative sleep, improved daytime functioning, or treatment of a sleep disorder.

The postmenopausal abstract’s primary endpoint was a symptom diary score, not a sleep test. It cannot determine whether any night-sweat improvement occurred through fewer physiological events, reduced perceived severity, altered awakenings, or some combination. Establishing those pathways would require measurements capable of separating symptoms from sleep and awareness.

Product identity matters as well. The current US PROMETRIUM formulation contains peanut oil and is contraindicated in people allergic to peanuts. Findings about oral micronized progesterone do not automatically establish equivalent exposure or outcomes for compounded capsules, creams, vaginal preparations, or other formulations. The capsule ingredient guide explains why the exact product record is more informative than the hormone name alone.

Source 1 Source 2

The perimenopause trial answered a different question

A separate Canadian randomized trial enrolled 189 perimenopausal women, averaging 49.9 years, who had menstruated within the preceding year. After one baseline month, participants received three months of oral micronized progesterone or placebo. Its third-month primary score difference was −1.51, with a 95% confidence interval of −3.97 to 0.95; superiority was not established.

That interval included both no difference and a potentially important benefit. Participants reported better perceived night sweats and sleep quality on secondary questionnaires, but diary-recorded sleep problems did not differ at month three. Those findings address different measurements and do not convert the primary result into a positive one. The perimenopause trial analysis examines that distinction.

The full perimenopause article reports Canadian Institutes of Health Research funding, with study capsules, placebo, and an extension donation from Besins Healthcare International. It reports no serious adverse events, while also describing a physician-mandated progesterone discontinuation for new atrial fibrillation; causation was not established. These disclosures belong to that study, not automatically to the earlier postmenopausal trial.

Two progesterone symptom trials, without merging their conclusions

Study featurePostmenopausal trialPerimenopausal trial
Participants133 randomized; ages 44–62; 1–10 years after final menstruation189 randomized; mean age 49.9; menstruation within the preceding year
ScheduleFour-week run-in and 12-week interventionOne baseline month and three treatment months
Oral active arm300 mg at bedtime300 mg at bedtime
Primary score estimateAdjusted difference −4.3; 95% CI −6.6 to −1.9Adjusted rate difference −1.51; 95% CI −3.97 to 0.95
Analysis approach114 with baseline and on-treatment VMS dataIntention-to-treat analysis with multiple imputation; 176 completed
Main interpretationEvidence of lower average VMS score versus placeboPrimary result inconclusive; secondary perceived benefits reported

Source 1 Source 3

Symptom evidence and product authorization remain separate

The US PROMETRIUM label lists prevention of endometrial hyperplasia in postmenopausal women with a uterus receiving conjugated estrogen tablets, and treatment of secondary amenorrhea. It does not list progesterone-alone hot flashes or insomnia. A positive symptom trial does not itself create a labeled indication, and endometrial protection evidence answers a different question from symptom relief.

FDA announced labeling changes for an initial six menopausal hormone products in February 2026. That announcement does not mean all risks disappeared. The current PROMETRIUM label retains contraindications and warnings concerning conditions including unexplained genital bleeding, breast cancer, thromboembolic disease, and liver dysfunction. Neither the older trial nor a general hormone-therapy headline replaces the exact product label.

Editorial interpretation: the practical comparison is between documented medicine and care terms, not between advertising claims and the trial’s group average. Readers using the CoreAge Rx review or Winona review can check documentary terms without assuming either service offers the studied intervention or reproduces its results. Questions about symptom tracking and reassessment also belong in a whole-plan follow-up discussion.

Source 1 Source 2 Source 4

Questions about the evidence

Does the result mean 4.3 fewer hot flashes every day?

No. The −4.3 estimate is a difference in a score combining frequency and severity for daytime and nighttime symptoms. A score can fall because episodes become less severe, less frequent, or both. The abstract does not provide an adjusted episode-count result that would justify translating those points into a specific number of avoided daily hot flashes.

Source 1

Was this progesterone alone or progesterone added to estrogen?

The reported comparison tested oral micronized progesterone against placebo as treatment for vasomotor symptoms; it was not an estrogen-plus-progesterone comparison. That distinction matters because the PROMETRIUM label’s endometrial-protection indication involves women receiving conjugated estrogen tablets. Evidence for one purpose or combination should not be silently substituted for the other.

Source 1 Source 2

Did all 133 women finish and contribute complete results?

The abstract does not support that description. It reports 133 randomized women and an analysis of 114 with baseline and on-treatment VMS data. Qualifying data were available for 68 of 75 assigned progesterone and 46 of 58 assigned placebo. This does not establish complete diaries or full treatment completion for every analyzed participant.

Source 1

Did the trial prove that progesterone improves sleep?

Not from its reported primary endpoint. The postmenopausal abstract focused on a hot-flash and night-sweat score. A separate perimenopause study found improved perceived sleep quality on a secondary questionnaire, but not a month-three difference in diary-recorded sleep problems. Drowsiness warnings in the product label are safety information, not proof of restorative sleep.

Source 1 Source 3 Source 2

What would make the evidence more useful for everyday decisions?

Larger, longer studies in more varied populations could clarify durability and less common harms. Separate estimates for episode frequency, severity, night sweats, sleep, and meaningful individual response would make the average score easier to interpret. Transparent accounting for missing outcomes and direct comparisons with other treatments would also answer questions this placebo-controlled abstract leaves open.

Source 1 Source 3

What this evidence supports

The postmenopausal trial provides a placebo-controlled signal of benefit for oral micronized progesterone in healthy, screened women relatively early after menopause. Its strongest conclusion concerns a lower average frequency-weighted severity score near the end of 12 weeks. The interpretation becomes less certain when moving from that endpoint to daily episode counts, individual response, sleep mechanisms, broader populations, or long-term safety. Adverse-event withdrawals and incomplete outcome inclusion deserve attention alongside the favorable estimate. For capsule-focused readers, the essential distinction is between evidence that a historical oral study arm improved one measured outcome and evidence supporting a particular product, indication, or ongoing care arrangement.

Research access and limitations

The postmenopausal analysis relies on the indexed primary report abstract, not an independently examined full article, protocol, or supplement. The separate perimenopause full research article and official US product and FDA material provide context; they do not supply missing postmenopausal estimates. Separate perimenopause protocols and supplementary files were not independently examined.

Sources for this article

Source type matters. A provider page describes an offer; an exact product label describes that medicine.

  1. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.Indexed primary study abstract · Checked 2026-10-21
  2. DailyMed — Prometrium progesterone capsule, Acertis Pharmaceuticals LLCCurrent exact oral Prometrium DailyMed label, updated July 23, 2026; patient leaflet revision February 2026. Does not establish provider supply. · Checked 2026-10-21
  3. Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial.Indexed primary study abstract and full research article · Checked 2026-10-21
  4. FDA: February 12, 2026 approval of menopausal hormone therapy labeling changesFederal regulator announcement · Checked 2026-10-21
How we use evidence ↗